OS Therapies shares are trading lower. The company requested a Type B Meeting to follow up on FDA guidance for its OST‑HER2 BLA, submitted b
OS Therapies shares are trading lower. The company requested a Type B Meeting to follow up on FDA guidance for its OST‑HER2 BLA, submitted biomarker data to the BEST program, added a synthetic control arm, and sought Rolling Review, RMAT and Breakthrough Therapy designations.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.